Nesrine El-Mezayen

Dr. Nesrine El-Mezayen

Faculty of Pharmacy, Pharos university in Alexandria

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2017 in Journal of Controlled Release
Verified
Journal Article
Closed access
NENesrine El-Mezayen
Nesrine El-Mezayen
WEWessam F. El-Hadidy
Wessam F. El-Hadidy
WEWessam M. El-Refaie
Wessam M. El-Refaie
TSTh.I. Shalaby
Th.I. Shalaby
MKMahmoud M. Khattab
Mahmoud M. Khattab
AEAiman S. El-Khatib
Aiman S. El-Khatib

1 August 2018 in Journal of Controlled Release
Verified
Journal Article
Closed access
NENesrine El-Mezayen
Nesrine El-Mezayen
WEWessam F. El-Hadidy
Wessam F. El-Hadidy
WEWessam M. El-Refaie
Wessam M. El-Refaie
TSThanaa I. Shalaby
Thanaa I. Shalaby
MKMahmoud M. Khattab
Mahmoud M. Khattab
AEAiman S. El-Khatib
Aiman S. El-Khatib

4 May 2022 in European Journal of Pharmaceutical Sciences
Verified
Journal Article
Open access
NENesrine El-Mezayen
Nesrine El-Mezayen
RMRehab.A. Abd el Moneim
Rehab.A. Abd el Moneim
SESafaa H. El-Rewini
Safaa H. El-Rewini
So far, the cholinergic hypothesis of Alzheimer's disease (AD) remains the fundamental explanation for the complex etiopathology of AD. However, therapeutics raising synaptic acetylcholine (Ach) or having cholinergic receptors agonistic activity had shown limited clinical efficacy, possibly, due to lacking capability to aggregate cholinergic receptors within the degenerated cholinergic neurons. Vitamin-B12 (B12) is an epigenetic modifier. It has a specific CNS transport system via the cubam receptors. The later enclose a cholinergic aggregator; agrin protein, suggesting that B12 administration may cause cholinergic receptors aggregation. Further, B12 involvement in homocysteine (Hcy) metabolism may restore blood brain barrier (BBB) integrity disrupted by elevated Hcy levels in AD. Here in, using a pharmacological model of cholinergic amnesia, three different B12 doses were compared to the standard of care; donepezil (DON) regarding cholinergic system modulation, and their effect on Hcy metabolic pathways. Further, AD-associated cerebro-vascular pathology was assessed by morphometric analyses of cerebro-vasculature morphology and ultrastructure using scanning and transmission electron-microscopes, respectively. Consequent effect on key AD-hallmarks and behavioral cognitive tests was also examined. The highest B12-tested dose (B12-HD) showed the greatest hippocampal cholinergic modulation with dose-dependent preferential upregulation of one cholinergic receptor over the other. Altered Hcy metabolism was proved to be a consequence of cholinergic disruption that was variably reversed by different B12 doses. In spite of equipotent effect of DON and B12-HD therapies in decreasing β-amyloid synthesis, B12-HD-treated group revealed the greatest restoration of BBB integrity indicating superior capability of β-amyloid clearance. Therefore, B12-HD therapy may represent a promising AD-modifying agent with extra-ability over conventional cholinergic modulators to aggregate cholinergic receptors.


13 July 2022 in Scientific Reports
Verified
Journal Article
Open access
PDF file
RIReham S. Ibrahim
Reham S. Ibrahim
NENesrine El-Mezayen
Nesrine El-Mezayen
AEAlaa A. El‐Banna
Alaa A. El‐Banna
Liver cirrhosis is a late-stage liver disease characterized by excessive fibrous deposition triggering portal-hypertension (PH); the prime restrainer for cirrhosis-related complications. Remedies that can dually oppose hepatic fibrosis and lower PH, may prevent progression into decompensated-cirrhosis. Different Astragalus-species members have shown antifibrotic and diuretic actions with possible subsequent PH reduction. However, A.spinosus and A.trigonus were poorly tested for eliciting these actions. Herein, A.spinosus and A.trigonus roots and aerial parts extracts were subjected to comprehensive metabolic-fingerprinting using UHPLC-MS/MS resulting in 56 identified phytoconstituents, followed by chemometric untargeted analysis that revealed variable metabolic profiles exemplified by different species and organ types. Consequently, tested extracts were in-vivo evaluated for potential antifibrotic/anticirrhotic activity by assessing specific markers. The mechanistic prospective to induce diuresis was investigated by analyzing plasma aldosterone and renal-transporters gene-expression. Serum apelin and dimethylarginine-dimethylaminohydrolase-1 were measured to indicate the overall effect on PH. All extracts amended cirrhosis and PH to varying extents and induced diuresis via different mechanisms. Further, An OPLS model was built to generate a comprehensive metabolic-profiling of A.spinosus and A.trigonus secondary-metabolites providing a chemical-based evidence for their efficacious consistency. In conclusion, A.spinosus and A.trigonus organs comprised myriad pharmacologically-active constituents that act synergistically to ameliorate cirrhosis and associated PH.

27 September 2023 in European Journal of Pharmacology
Verified
Journal Article
Closed access
ANAshraf A. Noah
Ashraf A. Noah
NENesrine El-Mezayen
Nesrine El-Mezayen
SESamar O. El-Ganainy
Samar O. El-Ganainy
IDInas E. Darwish
Inas E. Darwish
EAElham A. Afify
Elham A. Afify